01 junio 2013

EUROPEAN HEART JOURNAL. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention

Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Jung-Min Ahn, Jong-Young Lee, Won-Jang Kim, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park and Seung-Jung Park1

Aims: Peri-procedural myocardial infarction (MI) is a not infrequent complication of percutaneous coronary intervention (PCI), but conflicting information exists regarding incidence and prognostic impact of this event. We investigated frequency, causes, predictors, and clinical relevance of peri-procedural MI, using a large database.

01 junio 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Prolonged Clopidogrel Use After Bare Metal and Drug-Eluting Stent Placement

David P. Faxon, MD, Elizabeth Lawler, PhD, Melissa Young, MPH, Michael Gaziano, MD, PhD and Scott Kinlay, MBBS, PhD

Background—Current guidelines recommend combining clopidogrel with aspirin for up to 1 year after coronary stenting, but the value of clopidogrel beyond this time is uncertain.

01 junio 2013

EUROPEAN HEART JOURNAL. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

Jonas Oldgren, Lars Wallentin, John H. Alexander, Stefan James, Birgitta Jönelid, Gabriel Steg and Johan Sundström

Background: Oral anticoagulation in addition to antiplatelet treatment after an acute coronary syndrome might reduce ischaemic events but increase bleeding risk. We performed a meta-analysis to evaluate the efficacy and safety of adding direct thrombin or factor-Xa inhibition by any of the novel oral anticoagulants (apixaban, dabigatran, darexaban, rivaroxaban, and ximelagatran) to single (aspirin) or dual (aspirin and clopidogrel) antiplatelet therapy in this setting.

01 junio 2013

JACC. One-Stop Hybrid Coronary Revascularization Versus Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Multivessel Coronary Artery Disease. 3-Year Follow-Up Results From a Single Institution

Liuzhong Shen, MD; Shengshou Hu, MD; Haoran Wang, MD; Hui Xiong, MD; Zhe Zheng, MD; Lihuan Li, MD; Bo Xu, MD; Hongbing Yan, MD; Runlin Gao, MD

Objectives: This study sought to compare midterm clinical outcomes of 1-stop hybrid coronary revascularization (HCR) with coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for the treatment of multivessel coronary artery disease.

01 junio 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Transapical Coronary Artery Intervention

Oliver Dörr, MD, Helge Möllmann, MD, Stephan Achenbach, MD, Daniel Sedding, MD, Daniel Basic, MD, Christoph Liebetrau, MD, Sebastian Szardien, MD, Albrecht Elsässer, MD, Peter Roth, MD, Andreas Böning, MD, Christian Hamm, MD and Holger M. Nef, MD

The transfemoral and the transradial approach are the standard access routes for coronary angiography and percutaneous coronary interventions. A transapical left ventricular access is sometimes used for diagnostic purposes and has been described for structural cardiac interventions, but not for coronary artery interventions.1–4 A significant number of patients who undergo catheter-based aortic valve implantation also require coronary intervention. In selected cases, it may be desirable to perform coronary revascularization via the transapical access, for example if aortic disease makes a transfemoral or transradial approach impossible or may lead to complications. We report a case of successful transapical coronary intervention in a patient undergoing transapical catheter-based aortic valve implantation.

01 junio 2013

EUROPEAN HEART JOURNAL. The changing course of aortic valve disease in Scotland: temporal trends in hospitalizations and mortality and prognostic importance of aortic stenosis

Colin Berry, Suzanne M. Lloyd, Yanzhong Wang, Alyson MacDonald and Ian Ford

Aims: To investigate the contemporary clinical course of aortic valve disease types.

01 junio 2013

JACC. Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation. The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)

Vivek Y. Reddy, MD; Sven Möbius-Winkler, MD; Marc A. Miller, MD; Petr Neuzil, MD, PhD; Gerhard Schuler, MD; Jens Wiebe, MD; Peter Sick, MD; Horst Sievert, MD

Objectives: The purpose of this study was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin therapy.

01 junio 2012

JACC. Transcatheter Aortic Valve Replacement. Outcomes of Patients With Moderate or Severe Mitral Regurgitation

Stefan Toggweiler, MD; Robert H. Boone, MD; Josep Rodés-Cabau, MD; Karin H. Humphries, PhD; May Lee, PhD; Luis Nombela-Franco, MD; Rodrigo Bagur, MD; Alexander B. Willson, MBBS; Ronald K. Binder, MD; Ronen Gurvitch, MBBS; Jasmine Grewal, MD; Robert Moss, MD; Brad Munt, MD; Christopher R. Thompson, MD; Melanie Freeman, MBBS; Jian Ye, MD; Anson Cheung, MD; Eric Dumont, MD; David A. Wood, MD; John G. Webb, MD

Objectives: The aim of this study was to evaluate the impact of mitral regurgitation (MR) on outcomes after transcatheter aortic valve replacement (TAVR) and the impact of TAVR on MR.

01 junio 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Risk Profile and 3-Year Outcomes From the SYNTAX Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Nested Registries

Stuart J. Head, MS; David R. Holmes, Jr, MD; Michael J. Mack, MD; Patrick W. Serruys, MD, PhD; Friedrich W. Mohr, MD, PhD; Marie-Claude Morice, MD; Antonio Colombo, MD; A. Pieter Kappetein, MD, PhD

Objectives: The aim of this study was to evaluate the use of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in “real-world” patients unsuitable for the alternative treatment.

01 junio 2013

CIRCULATION. Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention. An Updated Report from the National Cardiovascular Data Registry (2007–2012)

Dmitriy N. Feldman, MD; Rajesh V. Swaminathan, MD; Lisa A. Kaltenbach, MS; Dmitri V. Baklanov, MD; Luke K. Kim, MD; S. Chiu Wong, MD; Robert M. Minutello, MD; John C. Messenger, MD; Issam Moussa, MD; Kirk N. Garratt, MD; Robert N. Piana, MD; William B. Hillegass, MD; Mauricio G. Cohen, MD; Ian C. Gilchrist, MD; Sunil V. Rao, MD

Background—Radial access for percutaneous coronary intervention (r-PCI) is associated with reduced vascular complications; however, previous reports have shown that <2% of percutaneous coronary intervention (PCI) procedures in the United States are performed via the radial approach. Our aims were to evaluate temporal trends in r-PCI and compare procedural outcomes between r-PCI and transfemoral PCI.

01 junio 2013

EUROPEAN HEART JOURNAL. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies

Ganesan Karthikeyan, Nagendra Boopathy Senguttuvan, Jo Joseph, Niveditha Devasenapathy, Vinay K. Bahl and Balram Airan

Aims: Left-sided prosthetic valve thrombosis (PVT) occurs frequently in developing countries and causes major morbidity and mortality. Fibrinolytic therapy (FT) is most commonly used as treatment, but increases the risk of stroke and bleeding. Urgent surgery may be more efficacious and cause fewer complications. Our aim was to compare the efficacy and safety of urgent surgery and FT for the treatment of left-sided PVT.

01 junio 2013

JACC. Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents. 2-Year Follow-Up of the Randomized TWENTE Trial

Kenneth Tandjung, MD; Hanim Sen, MD; Ming Kai Lam, MD; Mounir W.Z. Basalus, MD; J. (Hans) W. Louwerenburg, MD; Martin G. Stoel, MD; K. Gert van Houwelingen, MD; Frits H.A.F. de Man, MD, PhD; Gerard C.M. Linssen, MD, PhD; Salah A.M. Saïd, MD, PhD; Mark B. Nienhuis, MD, PhD; Marije M. Löwik, PhD; Patrick M.J. Verhorst, MD, PhD; Job van der Palen, PhD; Clemens von Birgelen, MD, PhD

Objectives: The aim of this study was to assess the safety and efficacy of the implantation of Resolute zotarolimus-eluting stents (ZES) (Medtronic Inc., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months.

01 junio 2012

JACC. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study

Dietmar Trenk, PhD; Gregg W. Stone, MD; Meinrad Gawaz, MD; Adnan Kastrati, MD; Dominick J. Angiolillo, MD, PhD; Ulrike Müller, MD; Gert Richardt, MD; Joseph A. Jakubowski, PhD; Franz-Josef Neumann, MD

Objectives: This study sought to investigate the efficacy, safety, and antiplatelet effect of prasugrel as compared with clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after elective percutaneous coronary intervention (PCI).

01 junio 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Contemporary Incidence and Predictors of Stent Thrombosis and Other Major Adverse Cardiac Events in the Year After XIENCE V Implantation. Results From the 8,061-Patient XIENCE V United States Study

Srihari S. Naidu, MD; Mitchell W. Krucoff, MD; David R. Rutledge, PharmD; Vivian W. Mao, MD, MPH; Weiying Zhao, MD, PhD; Qing Zheng, MS; Olivia Wilburn, MD, PhD; Krishnankutty Sudhir, MD, PhD; Charles Simonton, MD; James B. Hermiller, MD

Objectives: The aim of this study was to identify predictors of clinical events after XIENCE V (Abbott Vascular, Santa Clara, California) stenting.

01 junio 2013

JACC. Risk Stratification of Resistant Hypertension in Chronic Kidney Disease∗

Larry A. Weinrauch, MD; Akshay S. Desai, MD, MPH; Hicham Skali, MD, MSc; John A. D Elia, MD

The contribution of resistant hypertension (RH) to morbidity and cost in chronic kidney disease (CKD) populations should not be understated. Failure to control blood pressure (BP) inevitably heralds renal deterioration as well as accompanying increases in cardiovascular morbidity and mortality. Successful antihypertensive treatment to guideline-recommended targets is challenging, due to intravascular volume expansion (sodium/fluid retention) and treatment-related adverse effects limiting patient adherence. The NHANES (National Health and Nutrition Examination Survey) and ALLHAT (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) trials both demonstrated that CKD itself is a predictor of cardiac events as a result of failure to achieve adequate BP control (1,). But to date the management of RH remains empirical, due to a paucity of scientific clinical outcomes data with suboptimal results.